We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Cancer DNA Biomarkers Detected by Lab-On-A-Chip Technique

By LabMedica International staff writers
Posted on 28 Dec 2016
Miniaturized lab-on-chip approaches are prime candidates for developing viable diagnostic tests and instruments because they are small, need only limited test volumes, and can be cost-effective.

Cancer is the second leading cause of death in the USA, making early, reliable diagnosis and treatment a priority for doctors. More...
Genomic biomarkers offer great potential for diagnostics and new forms of treatment, such as immunotherapy.

A team of scientists and engineers from the University of California, Santa Cruz (CA, USA) and Brigham Young University (Provo, UT, USA) developed an optofluidic analysis system that processes biomolecular samples starting from whole blood and then analyzes and identifies multiple targets on a silicon-based molecular detection platform. Instead of transferring relatively large (micro- to milliliters) samples between test tubes or using bulky analytical equipment, samples and reagents are handled on chip-scale devices with fluidic microchannels. This requires much smaller test volumes, and multiple functions can be integrated on a single device, improving speed, reliability and portability of these laboratory processes.

The scientists demonstrated blood filtration, sample extraction, target enrichment, and fluorescent labeling using programmable microfluidic circuits. They detected and identified multiple targets using a spectral multiplexing technique based on wavelength-dependent multi-spot excitation on an antiresonant reflecting optical waveguide chip. Specifically, they extracted two types of melanoma biomarkers, mutated cell-free nucleic acids, BRAFV600E and NRAS, from whole blood. They detected and identified these two targets simultaneously using the spectral multiplexing approach with up to a 96% success rate.

Holger Schmidt, PhD, a professor of electrical engineering and senior author of the study, said, “Our approach uses optofluidic chips where both fluid processing and optical sensing are done on a chip, allowing for further miniaturization and performance enhancements of the chip system. In the near term, we hope to build new diagnostic instruments for molecular diagnostics with applications in oncology and infectious disease detection, both viruses and (drug-resistant) bacteria.” The study was published in the December 2016 issue of the journal Biomicrofluidics.

Related Links:
University of California, Santa Cruz
Brigham Young University

Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
ESR Analyzer
TEST1 2.0
Gold Member
Collection and Transport System
PurSafe Plus®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Immunology

view channel
Image: The simple blood marker can predict which lymphoma patients will benefit most from CAR T-cell therapy (Photo courtesy of Shutterstock)

Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy

CAR T-cell therapy has transformed treatment for patients with relapsed or treatment-resistant non-Hodgkin lymphoma, but many patients eventually relapse despite an initial response. Clinicians currently... Read more

Pathology

view channel
Image: Determining EG spiked into medicinal syrups: Zoomed-in images of the pads on the strips are shown. The red boxes show where the blue color on the pad could be seen when visually observed (Arman, B.Y., Legge, I., Walsby-Tickle, J. et al. https://doi.org/10.1038/s41598-025-26670-1)

Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups

Medicinal syrups contaminated with toxic chemicals have caused the deaths of hundreds of children worldwide, exposing a critical gap in how these products are tested before reaching patients.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.